Innate Pharma (IPHA) Consolidated Net Income (2019 - 2025)

Innate Pharma (IPHA) has reported Consolidated Net Income for 7 consecutive years, with -$24.3 million the latest figure, recorded in Q2 2025.

• Quarterly Consolidated Net Income rose 13.81% year-over-year to -$24.3 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$108.8 million (down 13.6% YoY) and the FY2022 annual result came in at -$149072.0, up 98.21% from the prior year.
• Consolidated Net Income improved to -$24.3 million in Q2 2025 per IPHA's latest filing, from -$56.3 million in the prior quarter.
• Over the last five years, Consolidated Net Income for IPHA reached as high as -$83070.7 in Q2 2022 and fell as low as -$56.3 million in Q4 2024.
• A 5-year average of -$17.3 million and a median of -$8.6 million in 2023 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2022 — Consolidated Net Income soared 99.69% — and 2023, when it plunged 5678.63%.
• Year by year, Consolidated Net Income stood at -$8.3 million in 2021, then surged by 98.21% to -$149072.0 in 2022, then tumbled by 5678.63% to -$8.6 million in 2023, then slumped by 553.51% to -$56.3 million in 2024, then soared by 56.86% to -$24.3 million in 2025.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$24.3 million, -$56.3 million, and -$28.2 million for Q2 2025, Q4 2024, and Q2 2024 respectively.